Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Merial found in breach of NOAH promotion code
Medicines cabinet
NexGard Spectra claimed in its promotion that it provided protection to dogs against lungworm.

Company marketed off-label use of NexGard Spectra

Merial Animal Health breached rules in its promotion of NexGard Spectra to the veterinary profession, the National Office of Animal Health (NOAH) has found.

The ruling follows a complaint made by Zoetis UK, which related to the promotion of NexGard Spectra to the veterinary profession via telephone conversations and webinars.

NexGard Spectra claimed in its promotion that it provided protection to dogs against lungworm, which is not indicated in it Summary of Product Characteristics (SPC).

This promotion was on a veterinary practice website, where it was suggested that such a licence was expected to be granted in the future. The information is believed to have come from a Merial company employee.

During a NOAH Code of Practice Committee, members came to the unanimous decision that Merial had been promoting an off-label use of NexGard Spectra, contrary to Code of Practice clauses.

In particular, the Committee took into account that the claim came via an employee of Merial during a webinar, during which the representative wrote: ‘You can use a product that is indicated for lungworm alongside NexGard’.

The Committee said this was indicative of a culture within Merial to suggest that NexGard Spectra could be used against lungworm.

During the committee, chaired by Guy Tritton, Merial’s representatives were asked to say what their response would be if a vet telephoned them about NexGard Spectra’s ability to be used against lungworm.

They explained their response would be and had been that there were studies showing its efficacy for lungworm, but that such use would be off-licence.

After reviewing the collective information, the Committee concluded that Merial was, in substance, promoting off-label use.
As such, Merial was also found to have failed short of the high ethical conduct expected of NOAH members, which is required under Clause 11.2.

Full details of the Code of Practice and rulings of the Committee are available at www.noah.co.uk.

Become a member or log in to add this story to your CPD history

FIVP launches CMA remedies survey

News Story 1
 FIVP has shared a survey, inviting those working in independent practice to share their views on the CMA's proposed remedies.

The Impact Assessment will help inform the group's response to the CMA, as it prepares to submit further evidence to the Inquiry Group. FIVP will also be attending a hearing in November.

Data will be anonymised and used solely for FIVP's response to the CMA. The survey will close on Friday, 31 October 2025. 

Click here for more...
News Shorts
CMA to host webinar exploring provisional decisions

The Competition and Markets Authority (CMA) is to host a webinar for veterinary professionals to explain the details of its provisional decisions, released on 15 October 2025.

The webinar will take place on Wednesday, 29 October 2025 from 1.00pm to 2.00pm.

Officials will discuss the changes which those in practice may need to make if the provisional remedies go ahead. They will also share what happens next with the investigation.

The CMA will be answering questions from the main parties of the investigation, as well as other questions submitted ahead of the webinar.

Attendees can register here before Wednesday, 29 October at 11am. Questions must be submitted before 10am on 27 October.

A recording of the webinar will be accessible after the event.